Prognostic Utility of Biomarkers in Predicting of One-Year Outcomes in Patients with Aortic Stenosis Treated with Transcatheter or Surgical Aortic Valve Implantation

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Parenica, Jiri ^a,b,c   Nemec, Petr ^c,d   Tomandl, Josef ^b   Ondrasek, Jiri ^d   Pavkova Goldbergova, Monika ^b   Tretina, Martin ^d   Jarkovsky, Jiri ^b   Littnerova, Simona ^b   Poloczek, Martin ^a,b   Pokorny, Petr ^d   Spinar, Jindrich ^a,b,c   Cermakova, Zdenka ^a,b   Miklik, Roman ^a   Malik, Petr ^d   Pes, Ondrej ^b   Lipkova, Jolana ^b   Tomandlova, Marie ^b   Kala, Petr ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^d Center of Cardiovascular Surgery and Transplantations   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; CREATININE; CYSTATIN C; CYSTEINE; CYSTEINYLGLYCINE; FERRIC REDUCING ABILITY OF PLASMA; GELATINASE A; GELATINASE B; GLUTATHIONE; HEMOGLOBIN; HOMOCYSTEINE; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRITE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

AGED; AORTA STENOSIS; AORTA VALVE PROSTHESIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EDWARDS PERIMOUNT BIOPROSTHESIS; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATIENT SAFETY; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCORING SYSTEM; SURGICAL RISK; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ALGORITHMS; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; CARDIAC CATHETERIZATION; EXTRACELLULAR MATRIX; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; KIDNEY; MALE; MALONDIALDEHYDE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; ROC CURVE; TREATMENT OUTCOME;

EID: 84871303077     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048851     Document Type: Article

References (26)

1. Conradi L, Seiffert M, Treede H, Silaschi M, Baldus S, et al. (2012) Transcatheter aortic valve implantation versus surgical aortic valve replacement: A propensity score analysis in patients at high surgical risk. J Thorac Cardiovasc Surg 143: 64-71.
2. Michel P, Roques F, Nashef SA, (2003) EuroSCORE Project Group (2003) Logistic or additive EuroSCORE for high-risk patients? Eur J Cardiothorac Surg 23: 684-687.
3. Ben-Dor I, Gaglia J, Barbash IM, Maluenda G, Hauville C, et al. (2011) Comparison between Society of Thoracic Surgeons Score and logistic EuroSCORE for predicting mortality in patients referred for transcatheter aortic valve implantation. Cardiovasc Revasc Med 12: 345-349.
4. Mack M, (2011) Risk Scores for Predicting Outcomes in Valvular Heart Disease: How Useful? Curr Cardiol Rep 13: 107-112.
5. Solbiati M, Prado M, (2011) Transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis reduces 1-year mortality compared to standard therapy. Intern Emerg Med 6: 161-162.
6. Himbert D, Descoutures F, Al-Attar N, Iung B, Ducrocq G, et al. (2009) Results of Transfemoral or Transapical Aortic Valve Implantation Following a Uniform Assessment in High-Risk Patients With Aortic Stenosis. J Am Coll Cardiol 54: 303-311.
7. Thomas M, Schymik G, Walther T, Himbert D, Lefevre T, et al. (2011) One-year outcomes of cohort 1 in the Edwards Sapien Aortic Bioprosthesis European Outcome (SOURCE) Registry: The European Registry of Transcatheter Aortic Valve Implantation Using Edwards SAPIEN Valve. Circulation 124: 125-425.
8. Pilgrim T, Wenaweser P, Meuli F, Huber C, Stortecky S, et al. (2011) Clinical outcome of high-risk patients with severe aortic stenosis and reduced left ventricular ejection fraction undergoing medical treatment or TAVI. PLoS One 6: e27556.
9. Sinning JM, Ghanem A, Steinhäuser H, Adenauer V, Hammerstingl C, et al. (2010) Renal Function as Predictor of Mortality in Patients After Percutaneous Transcatheter Aortic Valve Implantation. JACC: Cardiovasc Interv 3: 1141-1149.
10. Spargias K, Polymeros S, Dimopoulos A, Manginas A, Pavlides G, et al. (2011) The Predictive Value and Evolution of N-Terminal Pro-B-Type Natriuretic Peptide Levels Following Transcutaneous Aortic Valve Implantation. J Interv Cardiol 24: 462-469.
11. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, et al. (2011) Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 32: 205-217.
12. Nemec P, Ondrasek J, Malik P, Tretina M, Pokorny P, et al. (2012) Comparison of the surgical and transcatheter aortic valve replacement in high-risk patients. CorVasa 54: e76-e83.
13. Walther T, Dewey T, Borger MA, Kempfert J, Linke A, et al. (2009) Transapical aortic valve implantation: Step by step. Ann Thorac Surg 87: 276-283.
14. Cribier A, Litzler PY, Eltchaninoff H, Godin M, Tron C, et al. (2009) Technique of transcatheter aortic valve implantation with the Edwards-Sapien heart valve using the transfemoral approach. Herz 34: 347-356.
15. Benzie IFF, Strain JJ, (1996) The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP Assay. Anal Biochem 239: 70-76.
16. Khoschsorur GA, Winklhofer-Roob BM, Rabl H, Auer Th, Pent Z, et al. (2000) Evaluation of a sensitive HPLC method for the determination of Malondialdehyde, and application of the method to different biological meterials. Chromatographia 52: 181-184.
17. Vester B, Rasmussen K, (1991) High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 29: 549-554.
18. Pickering J, Endre Z, (2012) New metrics for assessing diagnostic potential of candidate biomarkers. Clin J Am Soc Nephrol 7: 1355-1364.
19. Walther T, Simon P, Dewey T, Wimmer-Greinecker G, Falk V, et al. (2007) Transapical Minimally Invasive Aortic Valve Implantation. Circulation 116: I240-245.
20. Rodés-Cabau J, Webb JG, Cheung A, Ye J, Dumont E, et al. (2010) Transcatheter Aortic Valve Implantation for the Treatment of Severe Symptomatic Aortic Stenosis in Patients at Very High or Prohibitive Surgical Risk: Acute and Late Outcomes of the Multicenter Canadian Experience. J Am Coll Cardiol 55: 1080-1090.
21. Nuis RJ, Dager AE, van der Boon RM, Jaimes MC, Caicedo B, et al. (2012) Patients with aortic stenosis referred for TAVI: treatment decision, in-hospital outcome and determinants of survival. Neth Heart J 20: 16-23.
22. Kefer J, Beauloye C, Astarci P, Renkin J, Glineur D, et al. (2010) Usefulness of B-Type Natriuretic Peptide to Predict Outcome of Patients Treated by Transcatheter Aortic Valve Implantation. Am J Cardiol 106: 1782-1786.
23. Watanabe E, Matsuda N, Shiga T, Kajimoto K, Ajiro Y, et al. (2006) Significance of 8-Hydroxy-2GÇ-Deoxyguanosine Levels in Patients With Idiopathic Dilated Cardiomyopathy. J Card Fail 12: 527-532.
24. Velagaleti RS, Gona P, Sundström J, Larson MG, Siwik D, et al. (2010) Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol 30: 2283-2288.
25. Hansson J, Vasan RS, Ärnlöv J, Ingelsson E, Lind L, et al. (2011) Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One 6: e16185.
26. Zhou X, Li C, Xu W, Chen J, (2012) Trimetazidine Protects against smoking-induced left ventricular remodeling wia attenuating oxidative stress, apoptosis, and inflammation. PLoS One 7: E40424.